These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27459414)

  • 1. Disulphide cross linked pullulan based cationic polymer for improved gene delivery and efflux pump inhibition.
    S PS; R RM
    Colloids Surf B Biointerfaces; 2016 Oct; 146():879-87. PubMed ID: 27459414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redox sensitive cationic pullulan for efficient gene transfection and drug retention in C6 glioma cells.
    S S P; M R R
    Int J Pharm; 2017 Sep; 530(1-2):401-414. PubMed ID: 28779982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy.
    Chen L; Ji F; Bao Y; Xia J; Guo L; Wang J; Li Y
    Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):418-429. PubMed ID: 27770912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
    Zheng Z; Aojula H; Clarke D
    J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collagen synthesis promoting pullulan-PEI-ascorbic acid conjugate as an efficient anti-cancer gene delivery vector.
    Ambattu LA; Rekha MR
    Carbohydr Polym; 2015 Aug; 126():52-61. PubMed ID: 25933522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH-responsive polymeric micelles based on poly(2-ethyl-2-oxazoline)-poly(D,L-lactide) for tumor-targeting and controlled delivery of doxorubicin and P-glycoprotein inhibitor.
    Zhao Y; Zhou Y; Wang D; Gao Y; Li J; Ma S; Zhao L; Zhang C; Liu Y; Li X
    Acta Biomater; 2015 Apr; 17():182-92. PubMed ID: 25612838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Targeting Synergistic Drug Delivery by Self-Assembled Hybrid Nanovesicles to Overcome Drug Resistance.
    Gong MQ; Wu C; He XY; Zong JY; Wu JL; Zhuo RX; Cheng SX
    Pharm Res; 2017 Jan; 34(1):148-160. PubMed ID: 27738951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
    Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
    Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of p53 gene/DOX intracellular delivery and P-gp inhibition by pullulan thiomers on cancer cells:
    S S P; M R R
    J Mater Chem B; 2023 Feb; 11(6):1365-1377. PubMed ID: 36655691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells.
    Li PY; Lai PS; Hung WC; Syu WJ
    Biomacromolecules; 2010 Oct; 11(10):2576-82. PubMed ID: 20722436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.
    Li JM; Wang YY; Zhao MX; Tan CP; Li YQ; Le XY; Ji LN; Mao ZW
    Biomaterials; 2012 Mar; 33(9):2780-90. PubMed ID: 22243797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
    Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
    Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery.
    Tam YT; To KK; Chow AH
    Colloids Surf B Biointerfaces; 2016 Mar; 139():249-58. PubMed ID: 26724466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
    Wang F; Zhang D; Zhang Q; Chen Y; Zheng D; Hao L; Duan C; Jia L; Liu G; Liu Y
    Biomaterials; 2011 Dec; 32(35):9444-56. PubMed ID: 21903258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles.
    Gao Y; Chen L; Zhang Z; Chen Y; Li Y
    Biomaterials; 2011 Feb; 32(6):1738-47. PubMed ID: 21112086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
    Misra R; Das M; Sahoo BS; Sahoo SK
    Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
    Jin X; Mo R; Ding Y; Zheng W; Zhang C
    Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.